Prognostic Implication of a Cuproptosis-Related miRNA Signature in Hepatocellular Carcinoma

Figure 4

Validation of the robustness of the CRM model. (a) The distributions of the risk scores and survival status in test set; (b) the expression of 14 CRMs between two risk groups in test set; (c) Kaplan-Meier curves of the miRNA signature in test set; (d) the ROC analysis to estimate the predictive efficiency of the miRNA signature in test set; (e) subgroup Kaplan-Meier survival analysis.

(a)

(b)

(c)

(d)

(e)